Comparison of Cytokine Expression in Multiple Sclerosis Patients and Healthy Volunteers

  • Ateke Mousavi Nasl-khameneh Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
  • Abbas Mirshafiey Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Abdorreza Naser Moghadasi MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammad Reza Shiri-Shahsavar Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Mohammad Reza Eshraghian Department of Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Maryam Shadanian Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
  • Mina Abdolahi Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
  • Ali Akbar Saboor-Yaraghi Mail Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
Multiple sclerosis, T cells, Cytokine, Transcription factor

Abstract

Multiple sclerosis (MS) is an autoimmune disease with the impaired balance of CD4+T cells. This trial is a descriptive study to evaluate the expression of CD4+T cell cytokines, interleukin (IL) ‑2, IL‑4, IL‑17, TGF‑β, and respectively related transcription factors, including T-bet, GATA3, RORγt and FoxP3 in MS patients. Sixteen relapsing-remitting MS (RRMS) patients receiving interferon beta (IFN-β)-1a in the stable phase of the disease and 14 healthy control volunteers (HCs) were enrolled in this study. The expression of cytokines and transcription factors was evaluated in peripheral blood mononuclear cells (PBMCs) of patients using real time PCR. The results of this study showed that the expression of IL-2 (P≤0.05), IL-4 (P≤0.05), IL-17 (P≤0.05) and RORγt (P≤0.01) in PBMCs of RRMS patients were significantly higher than those in HCs. The expression of TGF‑β, GATA3, and FoxP3 were higher but the RORγt expression was lower in the patients than HCs without reaching significant value. Observed results indicated differences in immune system cytokines of healthy volunteers and the patients that were in the stable phase and under immunomodulatory therapy especially in proinflammatory mediators. Therefore, any therapeutic strategy to restore the immune system balance is desirable in RRMS patients.

References

Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 2013;19:S15-20.

Lovett-Racke AE, Yang Y, Racke MK. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 2011;1812:246-51.

Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res 2011;31:695-703.

Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014;13:668-77.

Fletcher J, Lalor S, Sweeney C, Tubridy N, Mills K. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010;162:1-11.

Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 2014;32:257-81.

Coffman RL. Origins of the TH1-TH2 model: a personal perspective. Nat Immunol 2006;7:539-42.

Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177:566-73.

Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol 2014;72:132-41.

Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord 2011;4:281-96.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.

Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis results of an international survey. Neurology 1996;46:907-11.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology 1983;33:1444.

Bitarafan S, Harirchian MH, Sahraian MA, Keramatipour M, Moghadam NB, Togha M, et al. Impact of vitamin A supplementation on RAR gene expression in multiple sclerosis patients. J Mol Neurosci 2013;51:478-84.

Logan J, Edwards KJ, Saunders NA, eds. Real-time PCR: current technology and applications. London: Caister Academic Press, 2009.

Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.

Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol 2010;64:331-6.

Harrirchian MH, Honarvar NM, Koohdani F, Bitarafan S, Siassi F, Jafarirad S, et al. The effect of vitamin a supplementation on disease progression, cytokine levels and gene expression in multiple sclerotic patients: study protocol for a randomized controlled trial. Acta Med Iran 2014;52:94-100.

Adachi K, Kumamoto T, Araki S. Interleukin-2 receptor levels indicating relapse in multiple sclerosis. Lancet 1989;333:559-60.

Sharief M, Thompson E. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatr 1993;56:169-74.

Legroux L, Arbour N. Multiple sclerosis and T lymphocytes: an entangled story. J Neuroimmune Pharmacol 2015;10:528-46.

Honarvar NM, Harirchian MH, Abdolahi M, Abedi E, Bitarafan S, Koohdani F, et al. Retinyl Palmitate Supplementation Modulates T-bet and Interferon Gamma Gene Expression in Multiple Sclerosis Patients. J Mol Neurosci 2016:1-6.

Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian M-A, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. Daru 2013;21:50.

Venken K, Hellings N, Liblau R, Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 2010;16:58-68.

Klotz L, Knolle P. Nuclear receptors: TH17 cell control from within. FEBS Lett 2011;585:3764-9.

Mottaghi A, Ebrahimof S, Angoorani P, Saboor‐Yaraghi AA. Vitamin A Supplementation Reduces IL‐17 and RORc Gene Expression in Atherosclerotic Patients. Scand J Immunol Suppl 2014;80:151-7.

Honarvar NM, Harirchian MH, Koohdani F, Siassi F, Abdolahi M, Bitarafan S, et al. The effect of vitamin a supplementation on retinoic acid-related orphan receptor γt (RORγt) and interleukin-17 (IL-17) gene expression in avonex-treated multiple sclerotic patients. J Mol Neurosci 2013;51:749-53.

Saboor-Yaraghi AA, Harirchian MH, Honarvar NM, Bitarafan S, Abdolahi M, Siassi F, et al. The effect of vitamin A supplementation on FoxP3 and TGF-β gene expression in Avonex-treated multiple sclerosis patients. J Mol Neurosci 2015;56:608-12.

Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung H-P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006;2:201-11.

Axtell RC, Raman C, Steinman L. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol 2013;44:114-20.

Manel N, Unutmaz D, Littman DR. The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat Immunol 2008;9:641-9.

Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005;81:45-52.

Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003;15:430-5.

Published
2018-02-17
How to Cite
1.
Mousavi Nasl-khameneh A, Mirshafiey A, Naser Moghadasi A, Shiri-Shahsavar MR, Eshraghian MR, Shadanian M, Abdolahi M, Saboor-Yaraghi AA. Comparison of Cytokine Expression in Multiple Sclerosis Patients and Healthy Volunteers. Acta Med Iran. 56(2):77-83.
Section
Articles